SUPN - Supernus secures $150M line of credit from UBS Bank USA
- Supernus Pharmaceuticals ( NASDAQ: SUPN ) said Tuesday it entered into a $150 million credit line agreement with UBS Bank USA, which can be drawn at any time.
- Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of the UBS Fixed Funding Rate plus the applicable percentage spread established in the credit line.
- Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of the UBS Variable Rate plus the applicable percentage spread established in the credit line.
For further details see:
Supernus secures $150M line of credit from UBS Bank USA